Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY 4,048.00
+68.00 (1.71%)
May 27, 2026, 1:30 PM JST
Revenue by Segment
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Pharmaceutical Business - Japan (Including Pharmaceutical Business - OTC and Others) | 229.24B | 216.28B | 216.94B | - | - | |||||
Pharmaceutical Business - Japan (Including Pharmaceutical Business - OTC and Others) Growth | 5.99% | -0.30% | - | - | - | |||||
Pharmaceutical Business - Americas | 300.44B | 278.26B | 232.38B | 212.74B | 172.02B | |||||
Pharmaceutical Business - Americas Growth | 7.97% | 19.74% | 9.23% | 23.68% | 20.46% | |||||
Pharmaceutical Business - China | 130.75B | 115.54B | 111.93B | 110.77B | 106.42B | |||||
Pharmaceutical Business - China Growth | 13.16% | 3.23% | 1.05% | 4.09% | 25.08% | |||||
Pharmaceutical Business - EMEA | 81.53B | 79.40B | 75.99B | 72.16B | 59.34B | |||||
Pharmaceutical Business - EMEA Growth | 2.69% | 4.48% | 5.31% | 21.60% | 7.42% | |||||
Pharmaceutical Business - East Asia Global South | 68.82B | 59.56B | 54.23B | 49.84B | 50.63B | |||||
Pharmaceutical Business - East Asia Global South Growth | 15.56% | 9.83% | 8.80% | -1.57% | 10.34% | |||||
Other Business | 14.60B | 40.37B | 50.29B | 59.97B | 129.95B | |||||
Other Business Growth | -63.84% | -19.73% | -16.14% | -53.85% | 117.01% | |||||
Pharmaceutical Business - Japan (Excl. Pharmaceutical Business - OTC Drugs) | - | - | - | 215.42B | 214.05B | |||||
Pharmaceutical Business - Japan (Excl. Pharmaceutical Business - OTC Drugs) Growth | - | - | - | 0.64% | -7.70% | |||||
Pharmaceutical Business - OTC and Others | - | - | - | 23.51B | 23.83B | |||||
Pharmaceutical Business - OTC and Others Growth | - | - | - | -1.36% | -5.25% | |||||
Total | 825.38B | 789.40B | 741.75B | 744.40B | 756.23B | |||||
Total Growth | 4.56% | 6.42% | -0.36% | -1.56% | 17.07% |
Revenue by Geography
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
United States (U.S.) | 293.14B | 272.99B | 243.14B | 231.36B | 172.50B | |||||
United States (U.S.) Growth | 7.38% | 12.28% | 5.09% | 34.12% | 9.42% | |||||
Americas (Excluding United States) | 16.95B | 13.59B | 10.61B | 7.94B | 54.22B | |||||
Americas (Excluding United States) Growth | 24.67% | 28.07% | 33.73% | -85.36% | 1845.57% | |||||
Europe | 70.99B | 74.29B | 90.53B | 86.03B | 126.75B | |||||
Europe Growth | -4.44% | -17.94% | 5.23% | -32.13% | 44.75% | |||||
China | 127.24B | 127.49B | 109.28B | 108.56B | 106.59B | |||||
China Growth | -0.20% | 16.66% | 0.66% | 1.85% | 25.58% | |||||
Others | 80.04B | 72.31B | 61.74B | 60.20B | 52.78B | |||||
Others Growth | 10.69% | 17.12% | 2.56% | 14.04% | 6.54% | |||||
Japan | 237.03B | 228.73B | 226.45B | 250.33B | 243.39B | |||||
Japan Growth | 3.63% | 1.01% | -9.54% | 2.85% | -7.64% | |||||
Total | 825.38B | 789.40B | 741.75B | 744.40B | 756.23B | |||||
Total Growth | 4.56% | 6.42% | -0.36% | -1.56% | 17.07% |
Source: S&P Global Market Intelligence.